Arbeiten aus der Klinik 2015

Transcrição

Arbeiten aus der Klinik 2015
Anzahl Publikationen:
Davon IF-Arbeiten:
Summe IF:
170
127
556.456
1.
Adorjan K, Koller G, Pogarell O
Die kritische Phase nach dem Entzug.
MMW Fortschr Med 2015; 157: 53-55. IF -
2.
Aichmüller C, Soyka M
Müdigkeit bei Suchterkrankungen.
Swiss Medical Forum 2015; 15: 391-394. IF -
3.
Antal A, Keeser D, Priori A, Padberg F, Nitsche MA
Conceptual and Procedural Shortcomings of the Systematic Review "Evidence
That Transcranial Direct Current Stimulation (tDCS) Generates Little-to-no
Reliable Neurophysiologic Effect Beyond MEP Amplitude Modulation in
Healthy Human Subjects: A Systematic Review" by Horvath and Co-workers.
Brain Stimul 2015; 8: 846-9. IF 4.793
4.
Aust S, Palm U, Padberg F, Bajbouj M
Transkranielle Gleichstromstimulation bei depressiven Störungen.
Nervenarzt 2015; 86: 1492-99. IF 0.806
5.
Ayache SS, Créange A, Farhat WH, Zouari HG, Lesage C, Palm U,
Abdellaoui M, Lefaucheur J-P
Cortical excitability changes over time in progressive multiple sclerosis.
Functional Neurology 2015; 30: 1-8. IF -
6.
Ayache SS, Palm U, Chalah MA, Nguyen R, Farhat WH, Créange A,
Lefaucheur JP
Orienting network dysfunction in progressive multiple sclerosis.
J Neurol Sci 2015; 351: 206-207. IF 2.126
7.
Badowska DM, Reich-Erkelenz D, Schmitt A, Falkai P
Pathways to personalized treatment strategies for depressive disorders.
Eur Arch Psychiatry Clin Neurosci 2015; 265: 1-3. IF 4.113
8.
Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller H-J;
WFSBP Task Force on Treatment Guidelines for Unipolar Depression
Disorders.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines
for biological treatment of unipolar depressive disorders. part 2: maintenance
treatment of major depressive disorder-update 2015.
World J Biol Psychiatry 2015; 16: 76-95. IF 4.159
9.
Bendfeldt K, Smieskova R, Koutsouleris N, Klöppel S, Schmidt A,
Walter A, Harrisberger F, Wrege J, Simon A, Taschler B, Nichols T,
Riecher-Rössler A, Lang UE, Radue EW, Borgwardt S
Classifying individuals at high-risk for psychosis based on functional brain
activity during working memory processing.
Neuroimage Clin 2015; 9: 555-63. IF 3.857
10.
Benetti S, Pettersson-Yeo W, Allen P, Catani M, Williams S, Barsaglini
A, Kambeitz-Ilankovic LM, McGuire P, Mechelli A
Auditory verbal hallucinations and brain dysconnectivity in the perisylvian
language network: a multimodal investigation.
Schizophr Bull 2015; 41: 192-200. IF 7.757
11.
Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, Kambeitz J,
Malhi S, Giampietro V, Williams S, Brammer M, Rubia K, Collier DA,
McGuire PK
Impairment of inhibitory control processing related to acute psychotomimetic
effects of cannabis.
Eur Neuropsychopharmacol 2015; 25: 26-37. IF 4.409
12.
Bhugra D, Ventriglio A, Kuzman MR, Ikkos G, Hermans MH, Falkai P,
Fiorillo A, Musalek M, Hoschl C, Dales J, Beezhold J, Rössler W,
Racetovic G, Gaebel W
EPA guidance on the role and responsibilities of psychiatrists.
Eur Psychiatry 2015; 30: 417-22. IF 3.912
13.
Born C, de la Fontaine L, Winter B, Müller N, Schaub A, Früstück C,
Schüle C, Voderholzer U, Cuntz U, Falkai P, Meisenzahl E
First results of a refeeding program in a psychiatric intensive care unit for
patients with extreme anorexia nervosa.
BMC Psychiatry 2015; 15: 57. IF 2.576
14.
Brendel M, Pogarell O, Xiong G, Delker A, Bartenstein P, Rominger A;
Alzheimer´s Disease Neuroimaging Initiative.
Depressive symptoms accelerate cognitive decline in amyloid-positive MCI
patients.
Eur J Nucl Med Mol Imaging 2015; 42: 716-24. IF 5.537
15.
Bridler R, Häberle A, Müller ST, Cattapan K, Grohmann R, Toto S,
Kasper S, Greil W
Psychopharmacological treatment of 2195 in-patients with borderline
personality disorder: A comparison with other psychiatric disorders.
16.
Bruch J, Kurz C, Vasiljevic A, Nicolino M, Arzberger T, Höglinger GU
Early neurodegeneration in the brain of a child without functional PKR-like
endoplasmic reticulum kinase.
J Neuropathol Exp Neurol 2015; 74: 850-7. IF 3.432
17.
Brunnauer A, Buschert V, Fric M, Distler G, Sander K, Segmiller F,
Zwanzger P, Laux G
Driving performance and psychomotor function in depressed patients treated
with agomelatine of venlafaxine.
Pharmacopsychiatry 2015; 48: 65-71. IF 1.474
18.
Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch
M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank
J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Datz C,
Schmelz R, Brückner S, Zeissig S, Stephan AM, Wodarz N, Devière J,
Clumeck N, Sarrazin C, Lammert F, Gustot T, Deltenre P, Völzke H,
Lerch MM, Mayerle J, Eyer F, Schafmayer C, Cichon S, Nöthen MM,
Nothnagel M, Ellinghaus D, Huse K, Franke A, Zopf S, Hellerbrand C,
Moreno C, Franchimont D, Morgan MY, Hampe J
A genome-wide association study confirms PNPLA3 and identifies TM6SF2
and MBOAT7 as risk loci for alcohol-related cirrhosis.
Nat Genet 2015; 47: 1443-8. IF 31.616
19.
Cassoli JS, Guest PC, Malchow B, Schmitt A, Falkai P, Martins-deSouza D
Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte
dysfunction: from structural findings to molecules.
npf Schizophrenia 2015; 1: 15034. IF -
20.
Cimander KF, Poehlke T, Soyka M
Erfahrungen mit der Umstellung von Methadon-Razemat auf Levomethadon
im Therapiealltag.
Suchtmed 2015; 17: 7-19. IF -
21.
Cross-Villasana F, Finke K, Hennig-Fast K, Kilian B, Wiegand I, Müller
HJ, Möller H-J, Töllner T
The speed of visual attention and motor-response decisions in adult attentiondeficit/hyperactivity disorder.
Biol Psychiatry 2015; 78: 107-15. IF 11.212
22.
Dabbert D, Zimmermann J, Toto S, Grohmann R
Ich-dystone Suizidgedanken nach Absetzen einer dreitägigen Sertralin-Gabe.
Psychopharmakotherapie 2015; 22: 212-3. IF -
23.
Dehning S, Burger MB, Krause D, Jobst A, Yundina E, Müller N, Meyer
S, Zill P, Buchheim A
Tourette syndrome is associated with insecure attachment and higher
aggression.
Int J Neurosci 2015; 125: 521-5. IF 1.717
24.
Diedrich A, Voderholzer U
Obsessive-compulsive personality disorder: a current review.
Curr Psychiatry Rep 2015; 17: 2. IF 2.858
25.
Dieterich DC, Rossner MJ
Dissecting the regional diversity of glial cells by applying –omic technologies.
e-neuroforum 2015; 6: 63-68. IF -
26.
Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D,
Nait-Oumesmar B, Schmitt A, Gebicke-Haerter PJ, Falkai P, Grünblatt
E, Palkovits M, Arzberger T, Kretzschmar H, Dexter DT, Reynolds R
Common mechanisms in neurodegeneration and neuroinflammation: a
BrainNet Europe gene expression microarray study.
J Neural Transm (Vienna) 2015; 122: 1055-68. IF 2.587
27.
Edbauer D, Arzberger T
Brain banks still yield high interest rates.
28.
Falkai P
Der Mensch im Mittelpunkt – Chancen der individualisierten Psychiatrie und
Psychotherapie.
Fortschr Neurol Psychiatr 2015; 83: 605. IF 0.803
29.
Falkai P
Nachruf auf Prof. Dr. Kurt Heinrich.
30.
Falkai P, Hasan A
Freud und Leid mit den Leitlinien.
Der Neurologe und Psychiater 2015; 16: 3-4 IF -
31.
Falkai P, Hasan A, Koutsouleris N
Chancen der individualisierten Psychiatrie und Psychotherapie am Beispiel
schizophrener Psychosen.
Die Psychiatrie 2015; 12: 255-260. IF -
32.
Falkai P, Rossner MJ, Schulze TG, Hasan A, Brzòzka MM, Malchow B,
Honer WG, Schmitt A
Kraepelin revisited: schizophrenia from degeneration to faild regeneration.
Mol Psychiatry 2015; 20: 671-6. IF 13.314
33.
Falkai P, Schmitt A
Erythropoietin as an innovative add-on therapy for depression.
34.
Falkai P, Schmitt A
Risikofaktoren für Depression und Angststörungen und der Einsatz von
Lichttherapie.
35.
Fichter MM
Anorektische und bulimische Essstörungen.
In: Berger M (Hrsg). Psychische Erkrankungen, Klinik und Therapie.
Elsevier, München, 2015, S. 547-563.
36.
Fichter M
Epidemiologie der Essstörungen.
In: Herpertz S, de Zwann M, Zipfel S (Hrsg).
Handbuch Essstörungen und Adipositas.
Springer, Berlin Heidelberg 2015, S. 45-55.
37.
Fichter MM, Quadflieg N, Gierk B, Voderholzer U, Heuser J
The Munich Eating and Feeding Disorder Questionnaire (Munich ED-Quest)
DSM-5/ICD-10: Validity, reliability, sensitivity to change and norms.
Eur Eat Disorders Rev 2015; 23: 229-240. IF 2.912
38.
Fountoulakis KN, Gonda X, Baghai TC, Baldwin DS, Bauer M, Blier P,
Gattaz W, Hasler G, Möller HJ, Tandon R, Vieta E, Kasper S
Report of the WPA section of pharmacopsychiatry on the relationship of
antiepileptic drugs with suicidality in epilepsy.
Int J Psychiatry Clin Pract 2015; 19: 158-67. IF 1.278
39.
Franke AG, Soyka M
Pharmakologisches Neuroenhancement aus Sicht der Suchtmedizin.
Fortschr Neurol Psychiatr 2015; 83: 83-90. IF 0.803
40.
Franke AG, Soyka M
Psychopharmakotherapie vs. Cognitive Neuroenhancement.
Suchtmed 2015; 17: 219-223. IF -
41.
Gaebel W, Falkai P, Sartorius N, Zielasek J
Leitlinien weltweit bei psychiatrischen Erkrankungen.
42.
Gaebel W, Zielasek J, Falkai P
Psychotic Disorders in ICD-11.
43.
Gade K, Malzahn D, Anderson-Schmid H, Strohmaier J, Meier S, Frank
J, Falkai PG, Rietschel M, Schulze TG
Functional outcome in major psychiatric disorders and associated clinical and
psychosocial variables: a potential cross-diagnostic phenotype for further
genetic investigations?
44.
Giese A, Arzberger T
In memoriam: Hans A. Kretzschmar (1953-2014).
45.
Großimlinghaus I, Falkai P, Gaebel W, Hasan A, Jänner M, Janssen B,
Reich-Erkelenz D, Grüber L, Böttcher V, Wobrock T, Ziesalek J; LVRKlinikverbund
Erhebung von Qualitätsindikatoren anhand von Routinedaten. Darstellung
eines Machbarkeitstests in 10 Fachkliniken für Psychiatrie und
Psychotherapie.
Nervenarzt 2015; 86: 1393-99. IF 0.806
46.
Grüber L, Falkai P, Hasan A
Depression bei Schizophrenie.
47.
Gürkov R, Berman A, Dietrich O, Flatz W, Jerin C, Krause E, Keeser D,
Ertl-Wagner B
MR volumetric assessment of endolymphatic hydrops.
Eur Radiol 2015; 25: 585-95. IF 3.640
48.
Guest PC, Iwata K, Kato TA, Steiner J, Schmitt A, Turck CW, Martinsde-Souza D
MK-801 treatment affects glycolysis in oligodendrocytes more than in
astrocytes and neuronal cells: insights for schizophrenia.
Front Cell Neurosci 2015; 12: 180. IF 4.609
49.
Haas I, Nitsche MA, Grohmann R, Rüther E, Degner D
Parästhesien und Gangunsicherheit bei sensomotorischer Polyneuropathie
unter Mirtazapin.
Psychopharmakotherapie 2015; 22: 256-9. IF -
50.
Hasan A, Brinkmann C, Strube W, Palm U, Malchow B, Rothwell JC,
Falkai P, Wobrock T
Investigations of motor-cortex cortical plasticity following facilitatory and
inhibitory transcranial theta-burst stimulation in schizophrenia: a proof-ofconcept study.
J Psychiatr Res 2015; 61: 196-204. IF 4.465
51.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF,
Thibaut F, Möller H-J, WFSBP Task Force on Treatment Guidelines
for Schizophrenia.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines
for biological treatment of schizophrenia. Part 3: Update 2015 Management
of special circumstances: Depression, suicidality, substance use disorders and
pregnancy and lactation.
52.
Hasan A, Wobrock T, Großimlinghaus I, Zielasek J, Janssen B, ReichErkelenz D, Kopp I, Gaebel W, Falkai P
Die Aktualisierung der DGPPN S3-Leitlinie Schizophrenie – aktueller Stand.
53.
Hasan A, Wobrock T, Palm U, Strube W, Padberg F, Falkai P,
Fallgatter A, Plewnia C
Hirnstimulationsverfahren zur Behandlung schizophrener Psychosen.
Nervenarzt 2015; 86: 1481-91. IF 0.806
54.
Hasan A, Wolff-Menzler-C, Pfeiffer S, Falkai P, Weidinger E, Jobst A,
Hoell I, Malchow B, Yeganeh-Doost P, Strube W, Quast S, Müller N,
Wobrock T
Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment
of schizophrenia: a bicentric randomized controlled pilot study.
55.
Heilbronner U, Hinrichs H, Heinze H-J, Zaehle
Caffeine differentially alters cortical hemodynamic activity during working
memory: a near infrared spectroscopy study.
BMC Res Notes 2015; 8: 520. IF -
56.
Heilbronner U, Malzahn D, Strohmaier J, Maier S, Frank J, Treutlein J,
Mühleisen TW, Forstner AJ, Witt SH, Cichon S, Falkai P, Nöthen MM,
Rietschel M, Schulze TG
A common risk variant in CACNA1C supports a sex-dependent effect on
longitudinal functional recovery from episodes of schizophrenia-spectrum but
not bipolar disorder.
57.
Hennig-Fast K, Michl P, Müller J, Niedermeier N, Coates U, Müller N,
Engel RR, Möller H-J, Reiser M, Meindl T
Obsessive-compulsive disorder – a question of conscience? An fMRI study of
behavioral and neurofunctional correlates of shame and guilt.
J Psychiatr Res 2015; 68: 354-62 IF 4.465
58.
Herold S, Kumar P, Wichert SP, Kretzschmar B, Bähr M, Rossner MJ,
Hein K
Neurodegeneration in Autoimmune Optic Neuritis Is Associated with Altered
APP Cleavage in Neurons and Up-Regulation of p53.
PLoS One 2015; 10: 0138852. IF 3.057
59.
Holl AK, Grohmann R, Leitmaier M, Painold A, Mörkl S, Toto S, Kasper
S
Pharmacotherapy of anxiety disorders in German-speaking countries: current
status and changes between 1994 and 2011.
60.
Ihl R, Bunevicius R, Frölich L, Winblad B, Schneider LS, Dubois B,
Burns A, Thibaut F, Kasper S, Möller H-J; WFSBP Task Force on
Mental Disorders in Primary Care; WFSBP Task Force on Dementia
World Federation of Societies of Biological Psychiatry guidelines for the
pharmacological treatment of dementias in primary care.
61.
Jobst A, Sabass L, Palagyi A, Bauriedl-Schmidt C, Mauer MC, Sarubin
N, Buchheim A, Renneberg B, Falkai P, Zill P, Padberg F
Effects of social exclusion on emotions and oxytocin and cortisol levels in
patients with chronic depression.
J Psychiatr Res 2015: 60; 170-77. IF 4.465
62.
Juraeva D, Treutlein J, Scholz H, Frank J, Degenhardt F, Cichon S,
Ridinger M, Mattheisen M, Witt SH, Lang M, Sommer WH, Hoffmann
P, Herms S, Wodarz N, Soyka M, Zill P, Maier W, Jünger E, Gaebel W,
Dahmen N, Scherbaum N, Schmäl C, Steffens M, Lucae S, Ising M,
Smolka MN, Zimmermann US, Müller-Myhsok B, Nöthen MM, Mann K,
Kiefer F, Spanagel R, Brors B, Rietschel M.
XRCC5 as a risk gene for alcohol dependence: evidence from a genome-wide
gene-set-based analysis and follow-up studies in Drosophila and humans.
Neuropsychopharmacol 2015; 40: 361-71. IF 6.399
63.
Kambeitz JP, Howes OD
The serotonin transporter in depression: Meta-analysis of in vivo and post
mortem findings and implications for understanding and treating depression.
J Affect Disord 2015; 186: 358-366. IF 3.570
64.
Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C,
Malchow B, Falkai P, Koutsouleris N
Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of
multivariate pattern recognition studies.
Neuropsychopharmacology 2015; 40: 1742-51. IF 6.399
65.
Karch S, Keeser D, Hümmer S, Paolini M, Kirsch V, Karali T, Kupka M,
Rauchmann BS, Chrobok A, Blautzik J, Koller G, Ertl-Wagner B,
Pogarell O
Modulation of craving related brain responses using real-time fMRI in
patients with alcohol use disorder.
PLoS One 2015; e0133034. IF 3.057
66.
Karch S, Pogarell O
Neurobiologie bei Zwangsstörung.
Psychologie in Österreich 2015; 1: 7-16. IF –
67.
Kasparbauer AM, Rujescu D, Riedel M, Pogarell O, Costa A, Meindl T,
la Fougère C, Ettinger U
Methylphenidate effects on brain activity as a function of SLC6A3 genotype
and striatal dopamine transporter availability.
Neuropsychopharmacology 2015; 30: 736-45. IF 6.399
68.
Kerkemeyer L, Mostardt S, Biermann J, Wasem J, Neumann A,
Walendzik A, Jahn R, Bartels C, Falkai P, Brannath W, Breunig-Lyriti
V, Mester B, Timm J, Wobrock T
Evaluation of an integrated care program for schizophrenia: concept and
study design.
69.
Klioueva NM, Rademaker MC, Dexter DT, Al-Sarraj S, Seilhean D,
Streichenberger N, Schmitz P, Bell JE, Ironside JW, Arzberger T,
Huitinga I
BrainNet Europe's Code of Conduct for brain banking.
70.
Kittel-Schneider S, Wobrock T, Scherk H, Schneider-Axmann T, Trost
S, Zilles D, Wolf C, Schmitt A, Malchow B, Hasan A, Backens M, Reith
W, Falkai P, Gruber O, Reif A
Influence of DGKH variants on amygdala volume in patients with bipolar
affective disorder and schizophrenia.
71.
Köhler S, Wiethoff K, Ricken R, Stamm T, Baghai TC, Fisher R,
Seemüller F, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller
H-J, Zeiler J, Heinz A, Bauer M, Adli M
Characteristics and differences in treatment outcome of inpatients with
chronic vs. episodic major depressive disorders.
J Affect Disord 2015; 173: 126-33. IF 3.570
72.
Koerner N, Schmidt P, Soyka M
Decision making and impulsiveness in abstinent alcohol-dependent people and
healthy individuals: a neuropsychological examination.
Stubstance Abuse Treatment, Prevention, and Policy 2015; 10: 24.
IF 1.713
73.
Koerte IK, Lin AP, Muehlmann M, Merugumala S, Liao H, Starr T,
Kaufmann D, Mayinger M, Steffinger D, Fisch B, Karch S, Heinen F,
Ertl-Wagner B, Reiser M, Stern RA, Zafonte R, Shenton ME
Altered neurochemistry in former professional soccer players without a
history of concussion.
J Neurotrauma 2015; 32: 1287-93. IF 4.377
74.
Koller G, Pogarell O
Suchterkrankungen im Diagnostischen und Statistischen Manual Psychischer
Störungen DSM-5.
75.
Koller G, Preuss U, Lü O, Soyka M, Pogarell O
Alcohol-dependent subjects show different personality traits compared with
subjects with multiple substance dependence: preliminary data.
J Addict Med 2015; 9: 257-260. IF 2.065
76.
Koutsouleris N, Meisenzahl EM, Borgwardt S, Riecher-Rössler A, Frodl
T, Kambeitz J, Köhler Y, Falkai P, Möller H-J, Reiser M, Davatzikos C
Individualized differential diagnosis of schizophrenia and mood disorders
using neuroanatomical biomarkers.
Brain 2015; 138: 2059-073. IF 10.103
77.
Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, Smieskova R,
Studerus E, Kambeitz-Ilankovic L, von Saldern C, Cabral C, Reiser M,
Falkai P, Borgwardt S
Detecting the psychosis prodrome across high-risk populations using
neuroanatomical biomarkers.
78.
Kulla P, Schlegl S, Külz AK, Förstner U, Warschburger P, Voderholzer
U
Funktionalitäten von Zwangsstörungen – Entwicklung und Validierung eines
Fragebogens (FFZ).
Psychother Psychosom Med Psychol. 2015; 65: 213-222. IF 1.018
79.
Laoutidis ZG, Konstantinidis A, Grohmann R, Luckhaus C, Mobascher
J, Cordes J
Reversible amisulpride-induced elevation of creatine kinase (CK): a case series
from the German AMSP Pharmacovigilance project.
80.
Laqua C, Zill P, Koller G, Preuss U, Soyka M
Assoziation des MAOA-uVNTR-Polymorphismus mit antisozialem Verhalten
bei alkoholabhängigen Männern.
81.
Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G,
Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM,
Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM,
Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS,
Zangen A
Efficacy and safety of deep transcranial magnetic stimulation for major
depression: a prospective multicenter randomized controlled trial.
World Psychiatry 2015; 14: 64-73. IF 20.205
82.
Liu J, Zhu MW, Arzberger T, Wang LN
Frontotemporal lobar degeneration with accumulation of argyrophillic grains
and lewy bodies: a clinicopathological report.
J Alzheimers Dis 2015; 48: 55-8. IF 3.920
83.
Malchow B, Hasan A, Meyer K, Schneider-Axmann T, Radenbach KE,
Gruber O, Reith W, McIntosh AM, Schmitt A, Falkai P, Wobrock T
Family load impacts orbitofrontal volume in first-episode schizophrenia.
Psychiatry Res 2015; 232: 130-33. IF 2.466
84.
Malchow B, Keller K, Hasan A, Dörfler S, Schneider-Axmann T,
Hillmer-Vogel U, Honer WG, Schulz TG, Wobrock T, Schmitt A,
Falkai P
Effects of endurance training combined with cognitive remediation on
everyday functioning, symptoms and cognition in multiepisode schizophrenia
patients.
Schizophr Bull 2015; 41: 847.58. IF 7.757
85.
Malchow B, Strocka S, Frank F, Bernstein H-G, Steiner J, SchneiderAxmann T, Hasan A, Reich-Erkelenz D, Schmitz C, Bogerts B, Falkai P,
Schmitt A
Stereological investigation of the posterior hippocampus in affective disorders.
J Neural Transm 2015; 122: 1019-33. IF 2.587
86.
Meyronet D, Dorey A, Massoma P, Rey C, Alix E, Silva K, Perrin C,
Quadrio I, Perret-Liaudet A, Streichenberger N, Thomasset N,
Honnorat J, Arzberger T, Kretzschmar H
The workflow from post-mortem human brain sampling to cell
microdissection: a Brain Net Europe study.
J Neural Transm (Vienna) 2015; 122:975-91. IF 2.587
87.
Möller H-J, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M,
Barnikol UB, Lista S, Severus E, Maier W
DSM-5 reviewed from different angles: goal attainment, rationality, use of
evidence, consequences - part 1: general aspects and paradigmatic discussion
of depressive disorders.
88.
Möller H-J, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M,
Barnikol UB, Lista S, Severus E, Maier W
DSM-5 reviewed from different angles: goal attainment, rationality, use of
evidence, consequence - part 2: bipolar disorders, schizophrenia spectrum
disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and
stressor-related disorders, personality disorders, substance-related and
addictive disorders, neurocognitive disorders.
89.
Möller H-J, Czobor P
Pharmacological treatment of negative symptoms in schizophrenia.
90.
Möller H-J, Laux G, Deister A
Duale Reihe Psychiatrie, Psychosomatik und Psychotherapie.
Thieme, Stuttgart, 2015.
91.
Möller-Leimkühler AM
Gut getarnt ist halb gewonnen? Depression bei Männern.
In: Franz M, Karger A (Hrsg) Angstbeißer, Trauerkloß, Zappelphilipp?
Seelische Gesundheit bei Männern und Jungen.
Vandenhoeck & Ruprecht, 2015, S. 88-104.
92.
Mondino M, Brunelin J, Palm U, Brunoni AR, Poulet E, Fecteau S
Transcranial direct current stimulation for the treatment of refractory
symptoms of schizophrenia. Current evidence and future directions.
Curr Pharmaceutical Design 2015; 21: 3373-3383. IF 3.052
93.
Musil R
Weight gain as a consequence of treatment with antipsychotics.
94.
Musil R, Obermeier M, Russ P, Hamerle M
Weight gain and antipsychotics: a drug safety review.
Expert Opin Drug Saf 2015; 14: 73-96. IF 2.896
95.
Nedopil N, Taylor P, Gunn J
Forensic psychiatry in Europe: the perspective of the Ghent Group.
96.
Norman C, Wolff J, Hochlehnert A, Klein JP, Hohagen F, Lieb K,
Deckert J, Falkai P, Berger M, Herpertz SC
Aufwand und Finanzierung leitliniengerechter, psychotherapeutischer
Behandlung im Krankenhaus.
Nervenarzt 2015; 86: 534-41. IF 0.806
97.
Padberg F, Sabaß L, Dewald-Kaufmann J, Jobst A
Psychotherapie der chronischen Depression.
Nervenheilkunde 2015; 34: 880-887. IF -
98.
Paolini M, Keeser D, Ingrisch M, Werner N, Kindermann N, Reiser M,
Blautzik J
Resting-state networks in healthy adult subjects: a comparison between a 32element and an 8-element phased array head coil at 3.0 Tesla.
Acta Radiol 2015; 56: 605-13. IF 2.009
99.
Palm U
„Electricität“ – keine Wunder, aber beachtliche Wirkung.
Nervenarzt 2015; 86: 635-636. IF 0.806
100.
Palm U, Leitner B, Strube W, Hasan A, Padberg F
Safety of repeated twice-daily 30 minutes of 2 mA tDCS in depressed patients.
Int Neuropsychiatric Dis J 2015; 4: 168-171. IF –
101.
Palm U, Padberg F, Remi J
Transcranial direct current stimulation (tDCS) in a patient with PRES and
bipolar depression. Transkranielle Gleichstromstimuation (tDCS) bei PRES
und bipolarer Störung.
Fortschr Neurol Psychiatr 2015; 83: e11-e13. IF 0.803
102.
Palm U, Strube W, Bunse T, Bauer I, Dunkel G, Hasan A, Pfeiffer A,
Padberg F
Transkranielle Gleichstromstimulation in der Psychiatrie. Update 2015.
Nervenheilkunde 2015; 34: 1016-1025. IF -
103.
Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller
H-J, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perceczky R, Frölich
L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F
Cerebrospinal fluid cortisol and clinical disease progression in MCI and
dementia of Alzheimer´s type.
Neurobiol Aging 2015; 36: 601-7. IF 5.153
104.
Preuss UW, Koller G, Samochowiec A, Zill P, Samochowiec J,
Kucharska-Mazur J, Wong J, Soyka M
Serotonin and dopamine candidate gene variants and alcohol- and nonalcohol-related aggression.
Alcohol Alcoholism 2015; 50: 690-99. IF 2.724
105.
Quadflieg N, Fichter M
Verlauf der Bulimia nervosa und Bing-Eating-Störung.
In: Herpertz S, de Zwaan M, Zipfel S (Hrsg).
Handbuch Essstörungen und Adipositas. Springer, Berlin Heidelberg, 2015, S.
63-69.
106.
Ramos-Miguel A, Hercher C, Beasley C, Barr AM, Bayer TA, Falkai P,
Leurgans SE, Schneider JA, Bennett DA, Honer WG
Loss of Munc18-1 long splice variant in GABAergic terminals is associated
with cognitive decline and increased risk of dementia in a community sample.
Mol Neurodegener 2015; 10: 65. IF 6.510
107.
Reich-Erkelenz D, Schmitt A, Falkai P
Genetic and environmental risk factors in neurodevelopmental disorders.
108.
Psychiatrists´ self-stigma, the DGPPN guideline for psychosocial
interventions, and contemporary treatment strategies.
109.
Unravelling basic mechanisms in addiction and neuropsychiatric disorders.
110.
Rice SM, Fallon BJ, Aucote HM, Möller-Leimkühler AM, Treeby MS,
Amminger GP
Longitudinal sex differences of externalising and internalising depression
symptom trajectories: Implications for assessment of depression in men from
an online study.
Int J Soc Psychiatry 2015; 61: 236-40. IF 1.098
111.
Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S, Tatsch
K, Bartenstein P, la Fougère C, Koch W, Pogarell O
Altered serotonin and dopamine transporter availabilities in brain of
depressed patients upon treatment with escitalopram: A [123 I]β-CIT
SPECT study.
Eur Neuropsychoppharmacol 2015; 25: 873-81. IF 4.409
112.
Rüther T, Wissen F, Linhardt A, Aichert DS, Pogarell O, de Vries Hein
Electronic cigarettes – attitudes and use in Germany.
Nicotine & Tobacco Research 2015. IF 3.811
113.
Saia-Cereda VM, Cassoli JS, Schmitt A, Falkai P, Nascimento JM,
Martins-de-Souza D
Proteomics oft he corpus callosum unravel pivotal players in the dysfunction
of cell signaling, structure, and myelination in schizophrenia brains.
114.
Salize HJ, Voß E, Werner A, Falkai P, Hauth I
Behandlungspfade in der Versorgung von Patienten mit Schizophrenie und
Depression.
Nervenarzt 2015; 86: 1358-70. IF 0.806
115.
Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC,
Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M,
Lambert M, Lin CH, Möller H-J, Pelayo-Terán JM, Riedel M, Rujescu
D, Schimmelmann BG, Serretti A, Correll CU, Leucht S
Early improvement as a predictor of later response to antipsychotics in
schizophrenia: a diagnostic test review.
Am J Psychiatry 2015; 172:617-29. IF 13.505
116.
Sarubin N, Gutt D, Giegling I, Bühner M, Hilbert S, Krähenmann O,
Wolf M, Jobst A, Sabaß L, Rujescu D, Falkai P, Padberg F
Erste Analyse der psychometrischen Eigenschaften und Struktur der
deutschsprachigen 10- und 25-Item Version der Connor-Davidson Resilience
Scale (CD-RISC).
Zeitschrift für Gesundheitspsychologie 2015; 23: 112-122. IF -
117.
Sarubin N, Wolf M, Giegling I, Hilbert S, Naumann F, Gutt D, Jobst A,
Sabaß L, Falkai P, Rujescu D, Bühner M, Padberg F
Neuroticism and extraversion as mediators between positive/negative life
events and resilience.
Personality and Individual Differences 2015; 82: 193-198. IF 1.946
118.
Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, Möller HJ, Dean B
Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the
2013 CINP Think Tank.
Int J Neuropsychopharmacol 2015; 18: pyv042. IF 4.333
119.
Schennach R, Riedel M, Obermeier M, Seemüller F, Jäger M, Schmauss
M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter
J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M,
Möller H-J
What are depressive symptoms in acutely ill patients with schizophrenia
spectrum disorder?
Eur Psychiatry 2015; 30: 43-50. IF 3.912
120.
Schlegl S, Bürger C, Schmidt L, Herbst N, Voderholzer U
The potential of technology-based psychological interventions for anorexia
and bulimia nervosa: a systematic review and recommendations for future
research.
J Med Internet Res 2015; 17: e85. IF 4.532
121.
Schludi MH, May S, Grässer FA, Rentzsch K, Kremmer E, Küpper C,
Klopstock T; German Consortium for Frontotemporal Lobar
Degeneration; Bavarian Brain Banking Alliance, Arzberger T, Edbauer
D
Distribution of dipeptide repeat proteins in cellular models and C9orf72
mutation cases suggests link to transcriptional silencing.
Acta Neuropathol 2015; 130: 537-55. IF 11.360
122.
Schludi MH, May S, Grässer FA, Rentzsch K, Kremmer E, Küpper C,
Klopstock T; German Consortium for Frontotemporal Lobar
Degeneration; Bavarian Brain Banking Alliance, Arzberger T, Edbauer
D
Erratum to: Distribution of dipeptide repeat proteins in cellular models and
C9orf72 mutation cases suggests link to transcriptional silencing.
Acta Neuropathol 2015; 130: 557-58.
123.
Schmitt A, Falkai P
Classification and neurobiological concepts of mania, bipolar disorder and
major depression.
124.
Schmitt A, Falkai P
DGPPN guideline on anxiety disorders and cognitive dysfunction in the
elderly or patients with mulitple sclerosis.
125.
Schmitt A, Falkai P
Negative symptoms and therapy strategies in schizophrenia.
126.
Schmitt A, Falkai P
Schizophrenia spectrum and related neuropathology.
127.
Schmitt A, Malchow B, Keeser D, Falkai P, Hasan A
Neurobiologie der Schizophrenie. Aktuelle Befunde von der Struktur zu den
Molekülen.
Nervenarzt 2015; 86: 324-331. IF 0.806
128.
Schnell C, Shahmoradi A, Wichert SP, Mayerl S, Hagos Y, Heuer H,
Rossner MJ, Hülsmann S
The multispecific thyroid hormone transporter OATP1C1 mediates cellspecific sulforhodamine 101-labeling of hippocampal astrocytes.
Brain Struct Funct 2015; 220: 193-203. IF 5.811
129.
Shahmoradi A, Radyushkin K, Rossner MJ
Enhanced memory consolidation in mice lacking the circadian modulators
Sharp1 and -2 caused by elevated Igf2 signaling in the cortex.
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3582-9. IF 9.423
130.
Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, ManriqueHoyos N, Kongi K, Cantuti L, Hanisch UK, Philips MA, Rossner MJ,
Mann M, Simons M
Cell type- and brain region-resolved mouse brain proteome.
Nat Neurosci 2015; 18: 1819-31. IF 16.724
131.
Soyka M
Affektive und Angststörungen und komorbide Suchterkrankungen.
In: Walter M, Gouzoulis-Mayfrank E (Hrsg.)
Psychische Störungen und Suchterkrankungen.
Kohlhammer, Stuttgart 2015, S. 88-104.
132.
Soyka M
Alkohol als komorbide Störung bei Drogenabhängigkeit.
HIV&more 2015; 4: 18-19. IF -
133.
Soyka M
Alcohol-related disorders.
In: Wrigth JD (ed). International Ecyclopedia of the Social & Behavioral
Sciences. Elsevier, Oxford, 2015, Vol. 1, pp 507-512.
134.
Soyka M
Alcohol use disorders in opioid maintenance therapy: prevalence, clinical
correlates and treatment.
Eur Addict Res 2015; 21: 78-87. IF 2.367
135.
Soyka M
Benzodiazepine. Abhängigkeit von Hypnotika und Tranquilizern.
DNP Der Neurologe & Psychiater 2015; 16: 42-46. IF -
136.
Soyka M
Buprenorphine–naloxone buccal soluble film for the treatment of opioid
dependence: current update.
Expert Opin Drug Deliv 2015; 12: 339-47. IF 5.434
137.
Soyka M
Comorbidity of anxiety disorders and substance use.
In: Dom G, Moggi (ed).
Co-occuring Addictive and Psychiatric Disorders.
Springer, Berlin Heidelberg 2015. S 149-16.
138.
Soyka M
Neuroenhancement – die Illusion vom chemischen Glück.
Neurologie & Psychiatrie 2015; 4: 41-43. IF -
139.
Soyka M
New developments in the management of opioid dependence: focus on
sublingual buprenorphine-naloxone.
Substance Abuse and Rehabilitation 2015; 6: 1-14. IF -
140.
Soyka M
Pharmacotherapy in dual disorders.
In: Dom G, Moggi (ed).
Co-occuring Addictive and Psychiatric Disorders.
Springer, Berlin Heidelberg 2015. S. 279-306.
141.
Soyka M
Psychiatrische Begutachtung von Ärzten und Apothekern zu
approbationsrechtlichen Fragen.
In: Venzlaff U, Foerster K (Hrsg.)
Psychiatrische Begutachtung. Ein praktisches Handbuch für Ärzte und
Juristen.
Urban & Fischer, München, 2015, S. 725-729.
142.
Soyka M
Therapie der Alkoholabhängigkeit.
CME 2015; 12: 57-63. IF -
143.
Soyka M, Batra A
Benzodiazepinabhängigkeit (ICD-10 F.13.2)
In: Voderholzer U, Hohagen F (Hrsg.)
Therapie psychischer Erkrankungen. State of the Art.
Elsevier, München, 2015, S. 51-58.
144.
Soyka M, Baumgärtner G
Schweregradeinteilung für Suchterkrankungen im neuen DSM-5.
Swiss Arch Neurology Psychiatry 2015; 166: 45-50. IF -
145.
Soyka M, Fischer W
No evidence for development of tolerance after repeated use of propofol for
electroconvulsive therapy.
Pharmacopsychiatry 2015: 48: 7-10. IF 1.474
146.
Soyka M, Grunze H
Pharmacotherapy of Dual Disorders.
In: Dom G, Moggi F (eds). Co-occuring Addictive and Psychiatric Disorders.
Springer, Berlin Heidelberg, 2015, S. 279-306.
147.
Soyka M, Lieb M
Recent developments in pharmacotherapy of alcoholism.
148.
Soyka M, Zill P, Koller G, Samochowiec A, Grzywacz A, Preuss UW
Val158Met COMT polymorphism and risk of aggression in alcohol
dependence.
Addict Biol 2015; 20: 197-204. IF 4.547
149.
Spindelegger C, Papageorgiou K, Grohmann R, Engel R, Greil W,
Konstantinidis A, Agelink MW, Bleich S, Ruether E, Toto S, Kasper
Cardiovascular adverse reactions during antidepressant treatment: a drug
surveillance report of German-speaking countries between 1993 and 2010.
Int J Neuropsychopharmacol 2015; 18: pyu080. IF 4.333
150.
Stegmayer K, Usher J, Trost S, Henseler I, Tost H, Rietschel M, Falkai
P, Gruber O
Disturbed cortico-amygdalar functional connectivity as pathophysiological
correlate of working memory deficits in bipolar affective disorder.
151.
Strobel S, Grünblatt E, Riederer P, Heinsen H, Arzberger T, Al-Sarraj S,
Troakes C, Ferrer I, Monoranu CM
Changes in the expression of genes related to neuroinflammation over the
course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and
PPARγ.
152.
Strube W, Bunse T, Malchow B, Hasan A
Efficacy and interindividual variability in motor-cortex plasticity following
anodal tDCS and paired-associative stimulation.
Neural Plast 2015; 530423. IF 3.568
153.
Strube W, Bunse T, Malchow B, Hasan A
Corrigendum to „Efficacy and interindividual variability in motor-cortex
plasticity following anodal tDCS and paired-associative stimulation.
Neural Plast 2015; 903265.
154.
Strube W, Bunse T, Nitsche MA, Wobrock T, Aborowa R, Misewitsch
K, Herrmann M, Falkai P, Hasan A
Smoking restores impaired LTD-like plasticity in schizophrenia: a
transcranial direct current stimulation study.
Neuropsychopharmacol 2015; 40: 822-30. IF 6.399
155.
Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M,
Schmitt A, Nieratschker V, Witt SH, Rietschel M, Falkai P, Hasan A
BDNF-Val66Met-polymorphism impact on cortical plasticity in schizophrenia
patients: a proof-of-concept study.
Int J Neuropsychopharmacol 2015; 18: pyu040. IF 4.333
156.
Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J,
Arzberger T
Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular,
and Alzheimer-related co-pathologies.
157.
Thibaut F , Boutros NN, Jarema M, Oranje B, Hasan A, Daskalakis ZJ,
Wichniak A, Schmitt A, Riederer P, Falkai P; WFSBP Task Force on
Biological Markers
Consensus paper of the WFSBP Task Force on Biological Markers: criteria
for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology.
158.
Tordesillas-Gutierrez D, Koutsouleris N, Roiz-Santiañez R, Meisenzahl
E, Ayesa-Arriola R, Marco de Lucas E, Soriano-Mas C, Suarez-Pinilla P,
Crespo-Facorro B
Grey matter volume differences in non-affective psychosis and the effects of
age of onset on grey matter volumes: a voxelwise study.
Schizophr Res 2015; 164: 74-82. IF 4.453
159.
Tschirdewahn J, Vignaud P, Pfeiffer A, Nolden J, Padberg F, Palm U
Neue Therapieoption bei Depression: die transkranielle
Gleichstromstimulation.
MMW Fortschritte der Medizin 2015; 157: 46-49. IF -
160.
Van Eijk L, Groot ER, van Spronsen M, Maas YJ, Keeser D, Pogarell O,
Engelbregt HJ
Testing Van Gool´s Hypothesis: a method to predict side effects of
cholinesterase inhibitors in patients with cellular degenerative and vascular
dementia.
Advances Geriatrics 2015; 270657. IF -
161.
Voderholzer U, Schlegl S, Diedrich A, Külz AK, Thiel N, Hertenstein E,
Schwartz C, Rufer M, Herbst N, Nissen C, Hillebrand T, Osen B,
Stengler K, Jelinek L, Moritz S
Versorgung Zwangserkrankter mit kognitiver Verhaltenstherapie als
Behandlungsmethode erster Wahl.
Verhaltenstherapie 2015; 25: 183-190. IF 0.622
162.
Wessels H, Wagner M, Frommann I, Berning J, Pützfeld V, Janssen B,
Bottlender R, Maurer K, Möller H-J, Gaebel W, Häfner H, Maier W,
Klosterkötter J, Bechdolf A
Neuropsychologische Funktionen als Prädiktoren des Therapieerfolgs von
psychoedukativer, kognitiv verhaltenstherapeutischer Therapie bei Personen
mit erhöhtem Psychoserisiko.
Psychiatr Prax 2015; 42: 313-9. IF 1.612
163.
Whitfield JB, Rahman K, Haber PS, Day CP, Masson S, Daly AK,
Cordell HJ, Mueller S, Seitz HK, Liangpunsakul S, Westerhold C, Liang
T, Lumeng L, Foroud T, Nalpas B, Mathurin P, Stickel F, Soyka M,
Botwin GJ, Morgan TR, Seht D, GenomALC Consortium
Brief Report: Genetics of alcoholic cirrhosis –genom ALC multinational
study.
Alcohol Clin Exp Res 2015; 39: 836-42. IF 2.829
164.
Wigand M, Kubicki M, Clemm von Hohenberg C, Leicht G, Karch S,
Eckbo R, Pelavin PE, Hawley K, Rujescu D, Bouix S, Shenton ME,
Mulert C
Auditory verbal hallucinations and the interhemispheric auditory pathway in
chronic schizophrenia.
165.
Wobrock T, Guse B, Cordes J, Wölwer W, Winterer G, Gaebel W,
Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann
C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, SchneiderAxmann T, Falkai P, Hasan A
Left prefrontal high-frequency repetitive transcranial magnetic stimulation
for the treatment of schizophrenia with predominant negative symptoms: a
sham-controlled, randomized multicenter trial.
166.
Yousefi BH, Manook A, Grimmer T, Arzberger T, von Reutern B,
Henriksen G, Drzezga A, Förster S, Schwaiger M, Wester HJ
Characterization and first human investigation of FIBT, a novel fluorinated
Aβ plaque neuroimaging PET radioligand.
ACS Chem Neurosci 2015; 6: 428-37. IF 4.348
167.
Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER,
Derks EM, Evans P, Edlund CK, Crane J, Fagerness JA, Osiecki L,
Gallagher P, Gerber G, Haddad S, Illmann C, McGrath LM, Mayerfeld
C, Arepalli S, Barlassina C, Barr CL, Bellodi L, Benarroch F, Berrió GB,
Bienvenu OJ, Black DW, Bloch MH, Brentani H, Bruun RD, Budman CL,
Camarena B, Campbell DD, Cappi C, Silgado JC, Cavallini MC, Chavira
DA, Chouinard S, Cook EH, Cookson MR, Coric V, Cullen B, Cusi D,
Delorme R, Denys D, Dion Y, Eapen V, Egberts K, Falkai P, Fernandez
T, Fournier E, Garrido H, Geller D, Gilbert DL, Girard SL, Grabe HJ,
Grados MA, Greenberg BD, Gross-Tsur V, Grünblatt E, Hardy J,
Heiman GA, Hemmings SM, Herrera LD, Hezel DM, Hoekstra PJ,
Jankovic J, Kennedy JL, King RA, Konkashbaev AI, Kremeyer B, Kurlan
R, Lanzagorta N, Leboyer M, Leckman JF, Lennertz L, Liu C, Lochner
C, Lowe TL, Lupoli S, Macciardi F, Maier W, Manunta P, Marconi M,
McCracken JT, Mesa Restrepo SC, Moessner R, Moorjani P, Morgan J,
Muller H, Murphy DL, Naarden AL, Nurmi E, Ochoa WC, Ophoff RA,
Pakstis AJ, Pato MT, Pato CN, Piacentini J, Pittenger C, Pollak Y,
Rauch SL, Renner T, Reus VI, Richter MA, Riddle MA, Robertson MM,
Romero R, Rosário MC, Rosenberg D, Ruhrmann S, Sabatti C, Salvi E,
Sampaio AS, Samuels J, Sandor P, Service SK, Sheppard B, Singer HS,
Smit JH, Stein DJ, Strengman E, Tischfield JA, Turiel M, Valencia
Duarte AV, Vallada H, Veenstra-VanderWeele J, Walitza S, Wang Y,
Weale M, Weiss R, Wendland JR, Westenberg HG, Shugart YY, Hounie
AG, Miguel EC, Nicolini H, Wagner M, Ruiz-Linares A, Cath DC,
McMahon W, Posthuma D, Oostra BA, Nestadt G, Rouleau GA, Purcell
S, Jenike MA, Heutink P, Hanna GL, Conti DV, Arnold PD, Freimer NB,
Stewart SE, Knowles JA, Cox NJ, Pauls DL
Cross-disorder genome-wide analyses suggest a complex genetic relationship
between Tourette`s syndrome and OCD.
Am J Psychiatry 2015; 172: 82-93. IF 13.505
168.
Zhang T, Koutsouleris N, Meisenzahl E, Davatzikos C
Heterogeneity of structural brain changes in subtypes of schizophrenia
revealed using magnetic resonance imaging pattern analysis.
169.
Zohar J, Stahl S, Möller H-J, Blier P, Kupfer D, Yamawaki S, Uchida H,
Spedding M, Goodwin GM, Nutt D
A review of the current nomenclature for psychotropic agents and an
introduction tot he Neuroscience-based Nomenclature.
170.
Zhu MW, Liu J, Arzberger T, Wang LN, Wang ZF
Typical or atypical progressive supranuclear palsy: a comparative
clinicopathologic study of three Chinese cases.
Int J Clin Exp Pathol 2015; 8: 867.74. IF 1.581

Arbeiten aus der Klinik 2015

Transcrição

Documentos relacionados

2012

Drei Rheinländer klagen an RADAR: Bundeswehr hat uns krank

Besessenheit als Metapher für psychisches Leiden - seminare

SLEEP DISORDERS IN PSYCHIATRY AND THEIR TREATMENT

Pensionsversicherungsanstalt Wien

Elektronisches Briefpapier EPD Bruderholz

Was tun, wenn die antidepressive Behandlung versagt?

Fachhochschule Kiel: Henning Bakker

Behandlungsverläufe von jugendpsychiatrischer

Daniel MÃπller_2009 - UPD Abteilung für Psychotherapie

Die vollständige Publikation können Sie hier als